Loading
A phase 3 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Intismeran autogene in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) is a phase 3 interventional study registered as NCT06623422 by Merck Sharp & Dohme LLC, with 680 participants planned, started 2024-10-21 and due to reach its primary completion in 2033-05-16. Interventions recorded: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Paclitaxel.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Gemcitabine, Cisplatin and the tag pipeline.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.